Loading…
Anti-HIV Activity of Steric Block Oligonucleotides
: The unabated increase in spread of HIV infection worldwide has redoubled efforts to discover novel antiviral and virucidal agents that might be starting points for clinical development. Oligonucleotides and their analogs targeted to form complementary duplexes with highly conserved regions of the...
Saved in:
Published in: | Annals of the New York Academy of Sciences 2006-10, Vol.1082 (1), p.103-115 |
---|---|
Main Authors: | , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c4803-fdc71d1c7b144af99555e706eab8686eefd52112e73f898b419c709853d52cbe3 |
---|---|
cites | cdi_FETCH-LOGICAL-c4803-fdc71d1c7b144af99555e706eab8686eefd52112e73f898b419c709853d52cbe3 |
container_end_page | 115 |
container_issue | 1 |
container_start_page | 103 |
container_title | Annals of the New York Academy of Sciences |
container_volume | 1082 |
creator | IVANOVA, GABRIELA ARZUMANOV, ANDREY A. TURNER, JOHN J. REIGADAS, SANDRINE TOULMÉ, JEAN-JACQUES BROWN, DOUGLAS E. LEVER, ANDREW M.L. GAIT, MICHAEL J. |
description | : The unabated increase in spread of HIV infection worldwide has redoubled efforts to discover novel antiviral and virucidal agents that might be starting points for clinical development. Oligonucleotides and their analogs targeted to form complementary duplexes with highly conserved regions of the HIV RNA have shown significant antiviral activity, but to date clinical studies have been dominated by RNase H‐inducing oligonucleotide analog phosphorothioates (GEM 91 and 92) that have specificity and efficacy limitations. However, they have proven the principle that oligonucleotides can be safe anti‐HIV drugs. Newer oligonucleotide analogs are now available, which act as strong steric block agents of HIV RNA function. We describe our ongoing studies targeting the HIV‐1 trans‐activation responsive region (TAR) and the viral packaging signal (psi) with steric block oligonucleotides of varying chemistry and demonstrate their great potential for steric blocking of viral protein interactions in vitro and in cells and describe the first antiviral studies. Peptide nucleic acids (PNA) disulfide linked to cell‐penetrating peptides (CPP) have been found to have particular promise for the lipid‐free direct delivery into cultured cells and are excellent candidates for their development as antiviral and virucidal agents. |
doi_str_mv | 10.1196/annals.1348.033 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_20841346</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>20833211</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4803-fdc71d1c7b144af99555e706eab8686eefd52112e73f898b419c709853d52cbe3</originalsourceid><addsrcrecordid>eNqNkE1PwkAQhjdGI4ievZmevBV2u9v9OIJRQBES8SOeNu12alZKi92i8u8tluhRT5NMnvedzIPQKcFdQhTvRXkeZa5LKJNdTOkeahPBlM85DfZRG2MhfKkC2kJHzr1iTALJxCFqEUFYqChpo6CfV9YfjR-9vqnsu602XpF68wpKa7xBVpiFN8vsS5GvTQZFZRNwx-ggrY_CyW520MPV5f3FyJ_MhuOL_sQ3TGLqp4kRJCFGxISxKFUqDEMQmEMUSy45QJqEASEBCJpKJWNGlBFYyZDWexMD7aDzpndVFm9rcJVeWmcgy6IcirXTAZasfpz_B6S0PlWDvQY0ZeFcCalelXYZlRtNsN761I1PvfWpa5914mxXvY6XkPzyO4E1QBvgw2aw-atPT5_78-9av0lZV8HnTyoqF5oLKkL9NB1qenfNbwf4Rg_oF7rCj8c</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20833211</pqid></control><display><type>article</type><title>Anti-HIV Activity of Steric Block Oligonucleotides</title><source>Wiley</source><creator>IVANOVA, GABRIELA ; ARZUMANOV, ANDREY A. ; TURNER, JOHN J. ; REIGADAS, SANDRINE ; TOULMÉ, JEAN-JACQUES ; BROWN, DOUGLAS E. ; LEVER, ANDREW M.L. ; GAIT, MICHAEL J.</creator><creatorcontrib>IVANOVA, GABRIELA ; ARZUMANOV, ANDREY A. ; TURNER, JOHN J. ; REIGADAS, SANDRINE ; TOULMÉ, JEAN-JACQUES ; BROWN, DOUGLAS E. ; LEVER, ANDREW M.L. ; GAIT, MICHAEL J.</creatorcontrib><description>: The unabated increase in spread of HIV infection worldwide has redoubled efforts to discover novel antiviral and virucidal agents that might be starting points for clinical development. Oligonucleotides and their analogs targeted to form complementary duplexes with highly conserved regions of the HIV RNA have shown significant antiviral activity, but to date clinical studies have been dominated by RNase H‐inducing oligonucleotide analog phosphorothioates (GEM 91 and 92) that have specificity and efficacy limitations. However, they have proven the principle that oligonucleotides can be safe anti‐HIV drugs. Newer oligonucleotide analogs are now available, which act as strong steric block agents of HIV RNA function. We describe our ongoing studies targeting the HIV‐1 trans‐activation responsive region (TAR) and the viral packaging signal (psi) with steric block oligonucleotides of varying chemistry and demonstrate their great potential for steric blocking of viral protein interactions in vitro and in cells and describe the first antiviral studies. Peptide nucleic acids (PNA) disulfide linked to cell‐penetrating peptides (CPP) have been found to have particular promise for the lipid‐free direct delivery into cultured cells and are excellent candidates for their development as antiviral and virucidal agents.</description><identifier>ISSN: 0077-8923</identifier><identifier>EISSN: 1749-6632</identifier><identifier>DOI: 10.1196/annals.1348.033</identifier><identifier>PMID: 17145931</identifier><language>eng</language><publisher>Malden, USA: Blackwell Publishing Inc</publisher><subject>Anti-HIV Agents - administration & dosage ; Anti-HIV Agents - pharmacology ; antiviral ; Cells, Cultured ; Drug Delivery Systems - methods ; HIV ; HIV - genetics ; HIV Long Terminal Repeat - drug effects ; Human immunodeficiency virus ; Human immunodeficiency virus 1 ; Humans ; oligonucleotide ; Oligonucleotides - pharmacology ; Oligonucleotides - therapeutic use ; Peptide Nucleic Acids - therapeutic use ; RNA, Viral - drug effects ; steric block ; virucide</subject><ispartof>Annals of the New York Academy of Sciences, 2006-10, Vol.1082 (1), p.103-115</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4803-fdc71d1c7b144af99555e706eab8686eefd52112e73f898b419c709853d52cbe3</citedby><cites>FETCH-LOGICAL-c4803-fdc71d1c7b144af99555e706eab8686eefd52112e73f898b419c709853d52cbe3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27922,27923</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17145931$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>IVANOVA, GABRIELA</creatorcontrib><creatorcontrib>ARZUMANOV, ANDREY A.</creatorcontrib><creatorcontrib>TURNER, JOHN J.</creatorcontrib><creatorcontrib>REIGADAS, SANDRINE</creatorcontrib><creatorcontrib>TOULMÉ, JEAN-JACQUES</creatorcontrib><creatorcontrib>BROWN, DOUGLAS E.</creatorcontrib><creatorcontrib>LEVER, ANDREW M.L.</creatorcontrib><creatorcontrib>GAIT, MICHAEL J.</creatorcontrib><title>Anti-HIV Activity of Steric Block Oligonucleotides</title><title>Annals of the New York Academy of Sciences</title><addtitle>Ann N Y Acad Sci</addtitle><description>: The unabated increase in spread of HIV infection worldwide has redoubled efforts to discover novel antiviral and virucidal agents that might be starting points for clinical development. Oligonucleotides and their analogs targeted to form complementary duplexes with highly conserved regions of the HIV RNA have shown significant antiviral activity, but to date clinical studies have been dominated by RNase H‐inducing oligonucleotide analog phosphorothioates (GEM 91 and 92) that have specificity and efficacy limitations. However, they have proven the principle that oligonucleotides can be safe anti‐HIV drugs. Newer oligonucleotide analogs are now available, which act as strong steric block agents of HIV RNA function. We describe our ongoing studies targeting the HIV‐1 trans‐activation responsive region (TAR) and the viral packaging signal (psi) with steric block oligonucleotides of varying chemistry and demonstrate their great potential for steric blocking of viral protein interactions in vitro and in cells and describe the first antiviral studies. Peptide nucleic acids (PNA) disulfide linked to cell‐penetrating peptides (CPP) have been found to have particular promise for the lipid‐free direct delivery into cultured cells and are excellent candidates for their development as antiviral and virucidal agents.</description><subject>Anti-HIV Agents - administration & dosage</subject><subject>Anti-HIV Agents - pharmacology</subject><subject>antiviral</subject><subject>Cells, Cultured</subject><subject>Drug Delivery Systems - methods</subject><subject>HIV</subject><subject>HIV - genetics</subject><subject>HIV Long Terminal Repeat - drug effects</subject><subject>Human immunodeficiency virus</subject><subject>Human immunodeficiency virus 1</subject><subject>Humans</subject><subject>oligonucleotide</subject><subject>Oligonucleotides - pharmacology</subject><subject>Oligonucleotides - therapeutic use</subject><subject>Peptide Nucleic Acids - therapeutic use</subject><subject>RNA, Viral - drug effects</subject><subject>steric block</subject><subject>virucide</subject><issn>0077-8923</issn><issn>1749-6632</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><recordid>eNqNkE1PwkAQhjdGI4ievZmevBV2u9v9OIJRQBES8SOeNu12alZKi92i8u8tluhRT5NMnvedzIPQKcFdQhTvRXkeZa5LKJNdTOkeahPBlM85DfZRG2MhfKkC2kJHzr1iTALJxCFqEUFYqChpo6CfV9YfjR-9vqnsu602XpF68wpKa7xBVpiFN8vsS5GvTQZFZRNwx-ggrY_CyW520MPV5f3FyJ_MhuOL_sQ3TGLqp4kRJCFGxISxKFUqDEMQmEMUSy45QJqEASEBCJpKJWNGlBFYyZDWexMD7aDzpndVFm9rcJVeWmcgy6IcirXTAZasfpz_B6S0PlWDvQY0ZeFcCalelXYZlRtNsN761I1PvfWpa5914mxXvY6XkPzyO4E1QBvgw2aw-atPT5_78-9av0lZV8HnTyoqF5oLKkL9NB1qenfNbwf4Rg_oF7rCj8c</recordid><startdate>200610</startdate><enddate>200610</enddate><creator>IVANOVA, GABRIELA</creator><creator>ARZUMANOV, ANDREY A.</creator><creator>TURNER, JOHN J.</creator><creator>REIGADAS, SANDRINE</creator><creator>TOULMÉ, JEAN-JACQUES</creator><creator>BROWN, DOUGLAS E.</creator><creator>LEVER, ANDREW M.L.</creator><creator>GAIT, MICHAEL J.</creator><general>Blackwell Publishing Inc</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U9</scope><scope>H94</scope></search><sort><creationdate>200610</creationdate><title>Anti-HIV Activity of Steric Block Oligonucleotides</title><author>IVANOVA, GABRIELA ; ARZUMANOV, ANDREY A. ; TURNER, JOHN J. ; REIGADAS, SANDRINE ; TOULMÉ, JEAN-JACQUES ; BROWN, DOUGLAS E. ; LEVER, ANDREW M.L. ; GAIT, MICHAEL J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4803-fdc71d1c7b144af99555e706eab8686eefd52112e73f898b419c709853d52cbe3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Anti-HIV Agents - administration & dosage</topic><topic>Anti-HIV Agents - pharmacology</topic><topic>antiviral</topic><topic>Cells, Cultured</topic><topic>Drug Delivery Systems - methods</topic><topic>HIV</topic><topic>HIV - genetics</topic><topic>HIV Long Terminal Repeat - drug effects</topic><topic>Human immunodeficiency virus</topic><topic>Human immunodeficiency virus 1</topic><topic>Humans</topic><topic>oligonucleotide</topic><topic>Oligonucleotides - pharmacology</topic><topic>Oligonucleotides - therapeutic use</topic><topic>Peptide Nucleic Acids - therapeutic use</topic><topic>RNA, Viral - drug effects</topic><topic>steric block</topic><topic>virucide</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>IVANOVA, GABRIELA</creatorcontrib><creatorcontrib>ARZUMANOV, ANDREY A.</creatorcontrib><creatorcontrib>TURNER, JOHN J.</creatorcontrib><creatorcontrib>REIGADAS, SANDRINE</creatorcontrib><creatorcontrib>TOULMÉ, JEAN-JACQUES</creatorcontrib><creatorcontrib>BROWN, DOUGLAS E.</creatorcontrib><creatorcontrib>LEVER, ANDREW M.L.</creatorcontrib><creatorcontrib>GAIT, MICHAEL J.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Annals of the New York Academy of Sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>IVANOVA, GABRIELA</au><au>ARZUMANOV, ANDREY A.</au><au>TURNER, JOHN J.</au><au>REIGADAS, SANDRINE</au><au>TOULMÉ, JEAN-JACQUES</au><au>BROWN, DOUGLAS E.</au><au>LEVER, ANDREW M.L.</au><au>GAIT, MICHAEL J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Anti-HIV Activity of Steric Block Oligonucleotides</atitle><jtitle>Annals of the New York Academy of Sciences</jtitle><addtitle>Ann N Y Acad Sci</addtitle><date>2006-10</date><risdate>2006</risdate><volume>1082</volume><issue>1</issue><spage>103</spage><epage>115</epage><pages>103-115</pages><issn>0077-8923</issn><eissn>1749-6632</eissn><abstract>: The unabated increase in spread of HIV infection worldwide has redoubled efforts to discover novel antiviral and virucidal agents that might be starting points for clinical development. Oligonucleotides and their analogs targeted to form complementary duplexes with highly conserved regions of the HIV RNA have shown significant antiviral activity, but to date clinical studies have been dominated by RNase H‐inducing oligonucleotide analog phosphorothioates (GEM 91 and 92) that have specificity and efficacy limitations. However, they have proven the principle that oligonucleotides can be safe anti‐HIV drugs. Newer oligonucleotide analogs are now available, which act as strong steric block agents of HIV RNA function. We describe our ongoing studies targeting the HIV‐1 trans‐activation responsive region (TAR) and the viral packaging signal (psi) with steric block oligonucleotides of varying chemistry and demonstrate their great potential for steric blocking of viral protein interactions in vitro and in cells and describe the first antiviral studies. Peptide nucleic acids (PNA) disulfide linked to cell‐penetrating peptides (CPP) have been found to have particular promise for the lipid‐free direct delivery into cultured cells and are excellent candidates for their development as antiviral and virucidal agents.</abstract><cop>Malden, USA</cop><pub>Blackwell Publishing Inc</pub><pmid>17145931</pmid><doi>10.1196/annals.1348.033</doi><tpages>13</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0077-8923 |
ispartof | Annals of the New York Academy of Sciences, 2006-10, Vol.1082 (1), p.103-115 |
issn | 0077-8923 1749-6632 |
language | eng |
recordid | cdi_proquest_miscellaneous_20841346 |
source | Wiley |
subjects | Anti-HIV Agents - administration & dosage Anti-HIV Agents - pharmacology antiviral Cells, Cultured Drug Delivery Systems - methods HIV HIV - genetics HIV Long Terminal Repeat - drug effects Human immunodeficiency virus Human immunodeficiency virus 1 Humans oligonucleotide Oligonucleotides - pharmacology Oligonucleotides - therapeutic use Peptide Nucleic Acids - therapeutic use RNA, Viral - drug effects steric block virucide |
title | Anti-HIV Activity of Steric Block Oligonucleotides |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T10%3A40%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Anti-HIV%20Activity%20of%20Steric%20Block%20Oligonucleotides&rft.jtitle=Annals%20of%20the%20New%20York%20Academy%20of%20Sciences&rft.au=IVANOVA,%20GABRIELA&rft.date=2006-10&rft.volume=1082&rft.issue=1&rft.spage=103&rft.epage=115&rft.pages=103-115&rft.issn=0077-8923&rft.eissn=1749-6632&rft_id=info:doi/10.1196/annals.1348.033&rft_dat=%3Cproquest_cross%3E20833211%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4803-fdc71d1c7b144af99555e706eab8686eefd52112e73f898b419c709853d52cbe3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=20833211&rft_id=info:pmid/17145931&rfr_iscdi=true |